Free weekly newsletter
Get the free weekly contract digest
The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Pfizer Expands Collaboration with PostEra, Including Antibody-Drug Conjugates, in a $610 Million Partnership
Jan 07, 2025•over 1 year ago
Contract Type
partnership
San FranciscoBiotechnologyDescription
Pfizer has elected to expand its collaboration with PostEra, adding antibody-drug conjugates (ADCs) to its scope. The broadened partnership, valued at $610 million, aims to optimize payloads and develop new molecules through PostEra's machine learning platform.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months